Literature DB >> 30977539

Nomograms Predict Cancer-Specific and Overall Survival of Patients With Primary Limb Leiomyosarcoma.

Wei Wang1, Jianqiao Hong1, Jiahong Meng1, Haobo Wu1, Mingmin Shi1, Shigui Yan1, Yiting Huang2.   

Abstract

To date, there have been no data to predict the survival of patients with leiomyosarcoma from soft limb tissue because of the rarity of this disease. Nomograms have been widely applied in clinical oncology to precisely predict the survival of individual patients. This was a retrospective study to construct and validate nomograms to predict the cancer-specific survival (CSS) and overall survival (OS) of patients with primary limb leiomyosarcoma (PL-LMS). A total of 1,208 patients with LMS from limb soft tissue were collected from the Surveillance, Epidemiology, and End Results database from 1975 to 2015. We identified independent prognostic factors using univariate and multivariate Cox analyses. These prognostic factors were then included in the nomograms to predict 3- and 5-year CSS and OS rates. Finally, we validated the nomograms internally and externally. A total of 1208 patients were collected and divided into validation (N = 604) and training (N = 604) groups. Age, race, grade, tumor size, stage, and surgical types were demonstrated as independent prognostic factors for CSS and OS (all p < 0.05) and further used to construct the nomograms. The concordance index (C-index) for CSS was 0.857 for internal validation and 0.727 for external validation. The C-index for OS and CSS both demonstrated that the nomogram prediction agreed perfectly with actual survival. We developed nomograms to predict CSS and OS in PL-LMS patients and can benefit from using them to identify patients' mortality risk and make more precise assessments regarding survival.
© 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1649-1657, 2019. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  SEER database; nomograms; primary limb leiomyosarcoma; prognosis; survival

Year:  2019        PMID: 30977539     DOI: 10.1002/jor.24298

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  5 in total

1.  Nomograms for predicting long-term overall survival and cancer-specific survival in patients with primary urethral carcinoma: a population-based study.

Authors:  Hao Zi; Lei Gao; Zhaohua Yu; Chaoyang Wang; Xuequn Ren; Jun Lyu; Xiaodong Li
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

2.  Establishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma.

Authors:  Yi Liu; Xiaoling Lin; Lujiadai Xue; Yue Wen; Shuguang Wang; Xiaoyu Wang
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

3.  Prognosticators and Prognostic Nomograms for Leiomyosarcoma Patients With Metastasis.

Authors:  YuChi Zou; QianKun Yang; YuTong Wu; HongBo Ai; ZhongXiang Yao; ChengMin Zhang; Fei Luo
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

4.  Nomograms predicting local and distant recurrence and disease-specific mortality for R0/R1 soft tissue sarcomas of the extremities.

Authors:  Rita De Sanctis; Renata Zelic; Armando Santoro
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

5.  Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study).

Authors:  Ka-Yu Tse; Richard Wing-Cheuk Wong; Angel Chao; Shir-Hwa Ueng; Lan-Yan Yang; Margaret Cummings; Deborah Smith; Chiung-Ru Lai; Hei-Yu Lau; Ming-Shyen Yen; Annie Nga-Yin Cheung; Charlotte Ka-Lun Leung; Kit-Sheung Chan; Alice Ngot-Htain Chan; Wai-Hon Li; Carmen Ka-Man Choi; Wai-Mei Pong; Hoi-Fong Hui; Judy Ying-Wah Yuk; Hung Yao; Nancy Wah-Fun Yuen; Andreas Obermair; Chyong-Huey Lai; Philip Pun-Ching Ip; Hextan Yuen-Sheung Ngan
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.